Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in lymphoma
ChiCTR2400094077Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT) and lymphoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence of platelets < 50×10^9/L. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)lymphoma
Beyond the preview
Go deeper on ChiCTR2400094077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094077.